| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Nguyen M et al. | Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. | 2015 | Clin. Cancer Res. | pmid:26240273 |
| Ribrag V et al. | A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. | 2014 | Clin. Cancer Res. | pmid:24132920 |
| Krop I and Winer EP | Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. | 2014 | Clin. Cancer Res. | pmid:24135146 |
| Uppal H et al. | Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). | 2015 | Clin. Cancer Res. | pmid:25370470 |
| Menderes G et al. | SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. | 2017 | Clin. Cancer Res. | pmid:28679774 |
| Feng L et al. | Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. | 2014 | Clin. Cancer Res. | pmid:25294907 |
| Amiri-Kordestani L et al. | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. | 2014 | Clin. Cancer Res. | pmid:24879797 |
| Sabbaghi M et al. | Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. | 2017 | Clin. Cancer Res. | pmid:28821558 |
| Ogitani Y et al. | DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. | 2016 | Clin. Cancer Res. | pmid:27026201 |
| Baselga J et al. | Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. | 2016 | Clin. Cancer Res. | pmid:26920887 |
| Junutula JR et al. | Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. | 2010 | Clin. Cancer Res. | pmid:20805300 |
| Ikeda H et al. | The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. | 2009 | Clin. Cancer Res. | pmid:19509164 |
| Al-Katib AM et al. | Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. | 2009 | Clin. Cancer Res. | pmid:19509168 |
| Tijink BM et al. | A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. | 2006 | Clin. Cancer Res. | pmid:17062682 |
| Ostermann E et al. | Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. | 2008 | Clin. Cancer Res. | pmid:18628473 |
| LoRusso PM et al. | Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. | 2011 | Clin. Cancer Res. | pmid:22003071 |
| Blanc V et al. | SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. | 2011 | Clin. Cancer Res. | pmid:22003072 |
| Carol H et al. | The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. | 2013 | Clin. Cancer Res. | pmid:23426279 |
| Nicoletti R et al. | T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. | 2015 | Clin. Exp. Metastasis | pmid:25398397 |
| Bartsch R et al. | Activity of T-DM1 in Her2-positive breast cancer brain metastases. | 2015 | Clin. Exp. Metastasis | pmid:26303828 |
| Chudasama VL et al. | Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. | 2012 | Clin. Pharmacol. Ther. | pmid:22968044 |
| Wang J et al. | Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. | 2014 | Clin. Pharmacol. Ther. | pmid:24488143 |
| Garzone PD and Atkinson AJ | In search of physiologically based distribution volume estimates for macromolecules. | 2012 | Clin. Pharmacol. Ther. | pmid:22992670 |
| Tsuda M et al. | Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer. | 2016 | Cornea | pmid:27149538 |
| MartÃnez MT et al. | Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. | 2016 | Crit. Rev. Oncol. Hematol. | pmid:26318092 |
| Mustacchi G et al. | HER2-positive metastatic breast cancer: a changing scenario. | 2015 | Crit. Rev. Oncol. Hematol. | pmid:25748080 |
| Boyraz B et al. | Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. | 2013 | Curr Med Res Opin | pmid:23402224 |
| Nguyen-Ngoc T and Raymond E | Reinvention of chemotherapy: drug conjugates and nanoparticles. | 2015 | Curr Opin Oncol | pmid:25783982 |
| Mathew J and Perez EA | Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. | 2011 | Curr Opin Oncol | pmid:21986845 |
| Tumey LN and Han S | ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers. | 2017 | Curr Top Med Chem | pmid:29357803 |
| Lu D et al. | Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. | 2012 | Curr. Drug Metab. | pmid:22475266 |
| Shen BQ et al. | Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. | 2012 | Curr. Drug Metab. | pmid:22475269 |
| de Goeij BE and Lambert JM | New developments for antibody-drug conjugate-based therapeutic approaches. | 2016 | Curr. Opin. Immunol. | pmid:26963132 |
| Niculescu-Duvaz I | Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. | 2010 | Curr. Opin. Mol. Ther. | pmid:20521224 |
| Smith S | Technology evaluation: C242-DM1, ImmunoGen Inc. | 2001 | Curr. Opin. Mol. Ther. | pmid:11338934 |
| Smith SV | Technology evaluation: huN901-DM1, ImmunoGen. | 2005 | Curr. Opin. Mol. Ther. | pmid:16121706 |
| Smith SV | Technology evaluation: cantuzumab mertansine, ImmunoGen. | 2004 | Curr. Opin. Mol. Ther. | pmid:15663331 |
| Kim M et al. | Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. | 2014 | Curr. Opin. Obstet. Gynecol. | pmid:24335887 |
| Konecny GE | Emerging strategies for the dual inhibition of HER2-positive breast cancer. | 2013 | Curr. Opin. Obstet. Gynecol. | pmid:23241641 |
| Yang H et al. | Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division. | 2011 | Cytoskeleton (Hoboken) | pmid:21309084 |
| Edwards A et al. | Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. | 2011 | Dis Model Mech | pmid:21504911 |
| Zhang J et al. | Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis. | 2017 | Drug Des Devel Ther | pmid:29180848 |
| Shen BQ et al. | Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. | 2015 | Drug Metab Lett | pmid:26031461 |
| Walles M et al. | New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. | 2016 | Drug Metab. Dispos. | pmid:27122302 |
| Davis JA et al. | In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. | 2012 | Drug Metab. Dispos. | pmid:22752008 |
| Dhillon S | Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. | 2014 | Drugs | pmid:24659374 |
| Ballantyne A and Dhillon S | Trastuzumab emtansine: first global approval. | 2013 | Drugs | pmid:23620199 |
| Singh JC and Lichtman SM | Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. | 2015 | Drugs Aging | pmid:26645293 |
| Haddley K | Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer. | 2013 | Drugs Today | pmid:24308017 |
| Pode-Shakked N et al. | The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. | 2013 | EMBO Mol Med | pmid:23239665 |